GlaxoSmithKline has added a development candidate, ISIS-GSK3, to its collaboration with Isis Pharmaceuticals, Inc., triggering a $7 million milestone payment to Isis. ISIS-GSK3 is an antisense drug designed to inhibit the production of an undisclosed target to treat a common viral infection. Isis will develop ISIS-GSK3 to Phase II proof-of-concept. GSK will then have an exclusive option to in-license the program and further development and commercialization.
Isis is eligible to earn additional pre-licensing milestones as ISIS-GSK3 advances, as well as royalties on sales. The alliance uses Isis' antisense drug discovery platform to discover and develop new therapeutics against targets for rare and/or serious diseases.
"We are pleased with the progress of our collaboration with GSK and look forward to achieving further successes, including advancing ISIS-GSK3 into clinical studies. The benefit of GSK's expertise enables us to further expand the breadth of our pipeline into areas where effective new therapies are needed," said B. Lynne Parshall, chief operating officer of Isis.